Company Overview

Johnson & Johnson Services Inc. is involved in the R&D, manufacture, and sale of pharmaceuticals and medical devices. In September 2022, Johnson & Johnson named its consumer health business Kenvue, moving ahead with its plans to spin off the unit. In May 2023, Kenvue debuted as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol.

After the consumer health business split, Johnson & Johnson Services Inc. is organized into two business segments: Innovative Medicine and MedTech. The MedTech segment (previously referred to as Medical Devices) includes a broad portfolio of products used in the Interventional Solutions, OrthopFedics, Surgery, and Vision categories.

Johnson & Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies) offers diverse portfolios spanning multiple therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. It is a leading provider of gastroenterology drugs, including IBD therapies.

The company markets its products in over 175 countries and has approximately 131,900 global employees.

Company's Business Segments

• Innovative Medicine : Innovative Medicine segment inclues Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, Cardiovascular, Metabolism.
• MedTech : MEdTech segment inclues Surgery, Orthopaedics, Interventional Solutions, Vision